Loading
A phase 2 trial of docetaxel in lung cancer, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., not yet recruiting.
A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer is a phase 2, randomised interventional study registered as NCT06525350 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with a registry enrolment figure of 256 participants, started 2024-07 and due to reach its primary completion in 2026-12-25. Interventions recorded: Glumetinib tablets; HB1801 (docetaxel, albumin-bound）; Docetaxel. Conditions listed: Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression. Primary outcome: Dose-limiting toxicity(DLT) occurrence and incidence; Recommended phase 2 dose(RP2D) of the combination therapy; Adverse events (AE) and serious adverse events (SAE) occurrence and incidence. Lung eligibility wording from the registry: "Unresectable locally advanced or metastatic non-small cell lung cancer (IIIB, IIIC, or IV according to the 8th edition TNM staging standards of IASLC) confirmed by histology or cytology;". No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Docetaxel, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Unresectable stage III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Unresectable stage III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Unresectable stage III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Unresectable stage III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Unresectable stage III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Unresectable stage III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/